[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

2018 Diarrhea Drug Development- Pipeline Analysis Report

May 2018 | | ID: 2D6CBA997F8EN
VPAResearch

US$ 899.00 US$ 999.00 -10 %
Offer valid until December 31, 2024!

E-mail Delivery (PDF)

Download PDF Leaflet

Accepted cards
Wire Transfer
Checkout Later
Need Help? Ask a Question
With an estimated 1.5 million to 2 million people being affected worldwide, Diarrhea is the most catastrophic disease causing morbidity among children. Developing and poor countries are most susceptible to diarrhea.

Over 60 companies and universities are focusing on developing treatment options for Diarrhea.

To assist investigators and funding and regulatory organizations, VPA Research has come up with a comprehensive report on Diarrhea pipeline. The report provides insights into different therapeutic candidates in preclinical, research, discovery, NDA/IND, pre registration, phase 1, phase 2, and phase 3 trials). Drugs under development directly and through combination with other drugs are also included.

Current status, developmental phase, participating companies and entities, recent developments, orphan drug/fast track/other designations, drug class are provided for each Diarrhea pipeline product. Mechanism of Action and the target area of the pipeline product are also provided. Further, clinical and preclinical trials along with results of the trials are also included in the report.

In addition to complete details of each product, the report provides key trends in Diarrhea pipeline studies. The products under development are categorized according to their development phase, mechanism and company to provide detailed insights into the type of drugs being developed and the stages of development.
1 TABLE OF CONTENTS

1.1 List of Figures
1.2 List of Tables

2 DIARRHEA PIPELINE ANALYSIS

2.1 Disease and Pipeline Overview
2.2 Diarrhea Pipeline Snapshot
2.3 Diarrhea Pipeline by Phase
2.4 Diarrhea Pipeline by Company
2.5 Diarrhea Pipeline by Mechanism of Action

3 DIARRHEA- COMPANY WISE PIPELINE ANALYSIS

Ache Laboratories
Actelion Pharmaceuticals Ltd
Akthelia Pharmaceuticals
Albireo Pharma
Allergan Plc
Anatara Lifesciences Limited
Ardelyx Inc
AzurRx BioPharma Inc
Bharat Biotech International Ltd
Cosmo Pharmaceuticals NV
Genexine
Glycosyn LLC
GP Pharm SA
LTT Bio-Pharma Co
Miyarisan Pharmaceutical
Napo Pharmaceuticals In
Nippon Shinyaku Co Ltd
Novartis AG
Orphomed Inc
OstriGen
Pfizer Inc
Prokarium Ltd
RaQualia Pharma Inc
Rebiotix Inc
Recce Ltd
RedHill Biopharma Ltd
RxBio Inc
Scandinavian Biopharma Holding AB
Sigmoid Pharma
Summit Therapeutics Plc
Symberix Inc
Synthetic Biologics Inc
Syntiron LLC
Tasly Pharmaceutical Group Co Ltd
Zealand Pharma

4 DIARRHEA R&D PIPELINE SNAPSHOTS

Drug wise Pipeline Details
Therapeutic Candidate Name
Originator
Co-Developer/License Partner
Orphan Drug Designation
Development Phase
Mechanism of Action
Current Status
Ongoing Clinical Trial Details

5 RECENT DEVELOPMENTS IN DIARRHEA PIPELINE

6 APPENDIX

6.1 About VPA Research
6.2 Sources and Research Methodology

LIST OF FIGURES

Figure 1: Diarrhea Pipeline by Phase, H1- 2018
Figure 2: Diarrhea Pipeline by Companies, H1- 2018
Figure 3: Company Wise Pipeline Drug Phases, H1- 2018
Figure 4: Diarrhea Pipeline by Mechanism of Action, H1- 2018
Figure 5: Mechanism Wise Pipeline Drug Phases, H1- 2018

LIST OF TABLES

Table 1: Diarrhea Pipeline by Phase, H1- 2018
Table 2: Diarrhea Pipeline by Companies, H1- 2018
Table 3: Diarrhea Pipeline by Mechanism of Action, H1- 2018
Table 4: Ache Laboratories Diarrhea pipeline, May 2018
Table 5: Actelion Pharmaceuticals Ltd Diarrhea pipeline, May 2018
Table 6: Akthelia Pharmaceuticals Diarrhea pipeline, May 2018
Table 7: Albireo Pharma Diarrhea pipeline, May 2018
Table 8: Allergan Plc Diarrhea pipeline, May 2018
Table 9: Anatara Lifesciences Limited Diarrhea pipeline, May 2018
Table 10: Ardelyx Inc Diarrhea pipeline, May 2018
Table 11: AzurRx BioPharma Inc Diarrhea pipeline, May 2018
Table 12: Bharat Biotech International Ltd Diarrhea pipeline, May 2018
Table 13: Cosmo Pharmaceuticals NV Diarrhea pipeline, May 2018
Table 14: Genexine Diarrhea pipeline, May 2018
Table 15: Glycosyn LLC Diarrhea pipeline, May 2018
Table 16: GP Pharm SA Diarrhea pipeline, May 2018
Table 17: LTT Bio-Pharma Co Diarrhea pipeline, May 2018
Table 18: Miyarisan Pharmaceutical Diarrhea pipeline, May 2018
Table 19: Napo Pharmaceuticals In Diarrhea pipeline, May 2018
Table 20: Nippon Shinyaku Co Ltd Diarrhea pipeline, May 2018
Table 21: Novartis AG Diarrhea pipeline, May 2018
Table 22: Orphomed Inc Diarrhea pipeline, May 2018
Table 23: OstriGen Diarrhea pipeline, May 2018
Table 24: Pfizer Inc Diarrhea pipeline, May 2018
Table 25: Prokarium Ltd Diarrhea pipeline, May 2018
Table 26: RaQualia Pharma Inc Diarrhea pipeline, May 2018
Table 27: Rebiotix Inc Diarrhea pipeline, May 2018
Table 28: Recce Ltd Diarrhea pipeline, May 2018
Table 29: RedHill Biopharma Ltd Diarrhea pipeline, May 2018
Table 30: RxBio Inc Diarrhea pipeline, May 2018
Table 31: Scandinavian Biopharma Holding AB Diarrhea pipeline, May 2018
Table 32: Sigmoid Pharma Diarrhea pipeline, May 2018
Table 33: Summit Therapeutics Plc Diarrhea pipeline, May 2018
Table 34: Symberix Inc Diarrhea pipeline, May 2018
Table 35: Synthetic Biologics Inc Diarrhea pipeline, May 2018
Table 36: Syntiron LLC Diarrhea pipeline, May 2018
Table 37: Tasly Pharmaceutical Group Co Ltd Diarrhea pipeline, May 2018
Table 38: Zealand Pharma Diarrhea pipeline, May 2018


More Publications